Presentations on WM at ASH 2013 in New Orleans from our consortium on:
Elevated Von Willebrand Factor Antigen Serum Levels and their association with poor prognosis In patients with symptomatic Waldenstrom’s Macroglobulinemia (Efstathios Kastritis et al., Athens, Greece)
Disease unrelated mortality accounting for differences in survival in patients >75 Years with symptomatic Waldenström’s Macroglobulinemia (Efstathios Kastritis et al., Athens, Greece)
Newest update of the WM2 trial on the efficacy of Bortezomib in patients with advanced Waldenström Macroglobulinemia (V. Leblond et al., Paris, France)
